Home
Drugs
Obinutuzumab
Clinical Trials

Clinical Trials Related to Obinutuzumab

Related studies linked through entity extraction aliases.

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: COMPLETED
Phase: PHASE1/PHASE2

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Status: COMPLETED
Phase: PHASE1/PHASE2

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Status: COMPLETED
Phase: PHASE1

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Status: COMPLETED
Phase: PHASE1

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Status: COMPLETED
Phase: PHASE2

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Status: TERMINATED
Phase: PHASE1

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE1

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Status: TERMINATED
Phase: PHASE2

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Status: COMPLETED
Phase: PHASE1

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Status: RECRUITING
Phase: PHASE2

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Status: TERMINATED
Phase: PHASE1/PHASE2

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Status: WITHDRAWN
Phase: PHASE2

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Status: TERMINATED
Phase: PHASE1

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Status: COMPLETED
Phase: PHASE1

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Status: COMPLETED
Phase: PHASE2